Prostate Cancer Clinical Trial
Study of BMS-986158 in Subjects With Select Advanced Cancers
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Eligibility Criteria
Inclusion Criteria:
Must have select advanced cancers with specific genetic profiles
Must have received appropriate standard of care
At least one measurable lesion at baseline
Expected to have life expectancy of at least 3 months
Eastern Cooperative Oncology Group (ECOG) of 0 to 1
Exclusion Criteria:
Concomitant second malignancies
Uncontrolled or significant cardiovascular disease
Inadequate bone marrow function
Chronic gastrointestinal illness
Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor
Other protocol defined inclusion/exclusion criteria could apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 13 Locations for this study
Duarte California, 91010, United States
Aurora Colorado, 80045, United States
Boston Massachusetts, 02215, United States
Portland Oregon, 97239, United States
Philadelphia Pennsylvania, 19104, United States
Greenville South Carolina, 29605, United States
Melbourne Victoria, 3004, Australia
Ottawa Ontario, K1H 8, Canada
Lyon Cedex 08 , 69373, France
Villejuif , 94800, France
Barcelona , 08035, Spain
Madrid , 28050, Spain
Pamplona , 31008, Spain
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.